Target Name: CD248
NCBI ID: G57124
Review Report on CD248 Target / Biomarker Content of Review Report on CD248 Target / Biomarker
CD248
Other Name(s): CD248 antigen, endosialin | CD248 molecule | CD248_HUMAN | TEM1 | CD164L1 | 2610111G01Rik | CD164 sialomucin-like 1 | Tumor endothelial marker 1 | Endosialin | tumor endothelial marker 1 | CD248 molecule, endosialin

CD248: A Promising Drug Target and Biomarker for Cancer Treatment

Introduction

CD248 is a transmembrane protein that is expressed in various tissues, including the skin, hair, and nervous system. It is a member of the immunoglobulin superfamily and has been implicated in cell signaling, immune surveillance, and tissue repair. CD248 has also been identified as a potential drug target and biomarker for cancer treatment. In this article, we will explore the biology of CD248 and its potential as a drug target and biomarker.

CD248: Structure and Function

CD248 is a 21-kDa protein that consists of an extracellular domain, a transmembrane region, and an intracellular domain. The extracellular domain of CD248 consists of a N-terminal alpha helix and a C-terminal T-cell antigen (TCA) domain. The transmembrane region of CD248 is made up of a single 伪-helix and has been shown to be involved in the regulation of cell signaling pathways. The intracellular domain of CD248 includes a number of cytoplasmic retention domains (CRDs) that are involved in the regulation of protein stability and localization to the endoplasmic reticulum (ER).

CD248 is involved in a number of physiological processes, including cell signaling, inflammation, and tissue repair. It has been shown to be involved in the regulation of T cell proliferation and differentiation, as well as the regulation of skin barrier function. In addition, CD248 has been shown to play a role in the regulation of neurotransmitter release and pain perception.

CD248 as a Drug Target

CD248 has been identified as a potential drug target due to its involvement in a number of cellular processes that are associated with the development and progression of cancer. One of the key reasons for its potential as a drug target is its involvement in the regulation of cell signaling pathways, including the regulation of cell proliferation and apoptosis. In addition, CD248 has been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed to supply oxygen and nutrients to tumor cells.

CD248 has also been shown to be involved in the regulation of immune surveillance, which is important for the immune system's ability to detect and eliminate cancer cells. In addition, CD248 has been shown to play a role in the regulation of tissue repair, which is important for the immune system's ability to remove damaged or necrotic cells from the body.

CD248 as a Biomarker

CD248 has also been identified as a potential biomarker for cancer treatment. Its potential as a biomarker is based on its expression and/or its ability to interact with therapeutic agents. For example, CD248 has been shown to be downregulated in various types of cancer, including breast, lung, and ovarian cancer. This suggests that it may be a useful biomarker for the diagnosis and assessment of cancer recurrence.

In addition, some studies have shown that CD248 may be involved in the regulation of cancer cell migration and invasion. This suggests that it may be a useful biomarker for the assessment of cancer cell behavior and the effectiveness of potential therapeutic agents.

Conclusion

In conclusion, CD248 is a transmembrane protein that is involved in a number of physiological processes, including cell signaling, inflammation, and tissue repair. Its potential as a drug target and biomarker for cancer treatment is based on its involvement in the regulation of cell signaling pathways, including the regulation of cell proliferation and apoptosis, as well as its involvement in the regulation of immune survival, tissue repair, and cancer cell behavior. Further research is needed to fully understand the biology of CD248 and its potential as a drug

Protein Name: CD248 Molecule

Functions: May play a role in tumor angiogenesis

The "CD248 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CD248 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CD24P2 | CD27 | CD27-AS1 | CD274 | CD276 | CD28 | CD2AP | CD2BP2 | CD3 Complex (T Cell Receptor Complex) | CD300A | CD300C | CD300E | CD300LB | CD300LD | CD300LD-AS1 | CD300LF | CD300LG | CD302 | CD320 | CD33 | CD34 | CD36 | CD37 | CD38 | CD3D | CD3E | CD3G | CD4 | CD40 | CD40LG | CD44 | CD44-DT | CD46 | CD47 | CD48 | CD5 | CD52 | CD53 | CD55 | CD58 | CD59 | CD5L | CD6 | CD63 | CD68 | CD69 | CD7 | CD70 | CD72 | CD74 | CD79A | CD79B | CD8 | CD80 | CD81 | CD81-AS1 | CD82 | CD83 | CD84 | CD86 | CD8A | CD8B | CD8B2 | CD9 | CD93 | CD96 | CD99 | CD99L2 | CD99P1 | CDA | CDADC1 | CDAN1 | CDC123 | CDC14A | CDC14B | CDC14C | CDC16 | CDC20 | CDC20-DT | CDC20B | CDC20P1 | CDC23 | CDC25A | CDC25B | CDC25C | CDC26 | CDC27 | CDC27P2 | CDC34 | CDC37 | CDC37L1 | CDC37P1 | CDC40 | CDC42 | CDC42BPA | CDC42BPB | CDC42BPG | CDC42EP1 | CDC42EP2 | CDC42EP3